Genzyme held the rare disease day world with the second program of aid to associations of patients.
Cambridge (EE.)(UU.), March 2012.- a company of Sanofi, Genzyme (EURONEXT: SAN and NYSE: SNY), has announced its support for the rare disease day world through the Organization of a series of events to celebrate and recognize the global community of rare diseases. Held annually the last day of February, the world day for rare diseases to draw attention to these diseases as a major public health problem and foster the widespread recognition of the growing need for training, research and treatment.
As part of its activities for the day, Genzyme is pleased to announce the launch of its second annual global programme of aid, the Genzyme awards for leadership in the defense of patients (PAL Awards). Already opened the deadline for applications, the Genzyme PAL Awards seek to support organizations non-profit working for patients suffering from diseases of Lysosomal deposit (EDL), a group of hereditary rare diseases that cause progressive and debilitating health problems. Thanks to the fantastic reception of last year, which encompassed ideas and programs to raise awareness of the disease, patient education, assistance and subsidies around the world, Genzyme has doubled the amount awarded this year up to $100,000 in total. Prizes are awarded through a competitive application process, organizations seeking funding for new initiatives to support the community of patients with EDL.
Initiatives like the PAL Awards programme underline the commitment of Genzyme with the rare disease community and demonstrate the importance of higher education and a better understanding of these diseases with the aim of improving the quality of care to these patients worldwide ”, points out Dr. Rogerio VivaldiHead of rare diseases of Genzyme. For more than 30 years, Genzyme has proud of working with patients associations to promote the access to care and treatment of patients with rare diseases and special unmet medical needs ”.
In 2011, more than 50 organizations of patients around the world pointed to the Genzyme PAL awards program and 11 were selected by the external review Committee to win the PAL award.
We are a young patient organisation with a big heart ”, said Kenneth Mah, Vice President of the Association of disease rare in Singapore. are proud that Genzyme has recognized and chosen our Association as one of the 11 that will receive the PAL award of Genzyme. The PAL award funds are invaluable to the awareness of the community ”.
Other initiatives of Genzyme for the world day of rare diseases
On February 29, 2012 is the V day world of rare diseases, created by the Organization of patients EURORDIS and with the participation of organizations of patients around the world. There are nearly 7,000 rare diseases identified and many of them do not have treatment. Although every condition is unique, as a whole they affect millions of people. Genzyme is a participant of the world day for rare diseases-fixed and it has organized events in the world Genzyme sites focused on this year’s theme, solidarity ” these events include:
-presentations and testimonies of patients with rare diseases at the headquarters of Genzyme’s worldwide;
-participation in the official act of ERDF held in the Council of the Judicial power in Madrid and chaired by HRH the Princess of Asturias, and other authorities from the world of politics and health.
-participation in the campaign of the ERDF bracelet vaccine of hope ” with 1,400 employees participating in the centers of Sanofi and Genzyme, Spain and Portugal.
-China officesSerbia, Slovenia, Croatia, Costa Rica, Japan and India will work with hospitals and local organizations in defense of the patient to support the activities of the day.
More on the Genzyme awards for leadership in the defense of patients
Organizations can request a PAL award of Genzyme for programmes that support awareness about deposit disorders Lysosomal, Defense for the communities of patients, education and assistance of patients and support and communication networks. This aid programme complemented the existing aid programme of Genzyme and not replace the contributions made locally each year in support of advocacy groups. Proposals will be received by an external review Committee. Applications can submit until June 15, 2012, and will be announced the winners September 30, 2012.
About Genzyme, a company Sanofi
Genzyme has led the development and delivery of transformative therapies for patients with rare and debilitating diseases for more than thirty years. We reached our goals thanks to research of the highest quality and compassion and commitment of our employees. We focus on rare diseases and multiple sclerosis, and are committed to produce a positive impact on the lives of patients and families to whom we provide services. That is the objective that helps us guide and inspiration every day. The portfolio of transforming therapies of Genzyme, marketed in countries around the world, is the result of progress vital pioneers in medicine. As company Sanofi, Genzyme is benefiting from the scope and resources of one of the biggest pharmaceutical in the world, with a common commitment to improve the lives of patients.
About Sanofi
Sanofi, a leader in global and diversified health, discovers, develops and distributes therapeutic solutions aimed at the needs of patients. Sanofi has strengths in the field of health with seven platforms and growth: solutions for diabetes, human vaccines, innovative medicines, rare diseases, care, health, emerging markets and animal health. Sanofi is listed in her bosa Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Genzyme ® is a registered trademark of Genzyme Corporation. All rights reserved.
